Skip to content

The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach

The Early Therapeutic Efficacy of The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach: A Single-Center Retrospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06020287
Enrollment
233
Registered
2023-08-31
Start date
2020-09-01
Completion date
2022-12-27
Last updated
2023-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatectomy, Prostate Neoplasm

Brief summary

The goal of this observational study was to compare the perioperative outcomes, postoperative urinary control rates and positive surgical margin (PSM) rates of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach (AP-RARP) with the Retzius-sparing approach (RS-RARP) and anterior approach (anterior-RARP) in the treatment of prostate cancer. The main question it aims to answer was: • The early therapeutic efficacy of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach Participants has been underwent: * AP-RARP * RS-RARP * anterior-RARP Researchers compared the three groups to see if AP-RARP combines the advantages of anterior and posterior RARP and is a feasible surgical option for the treatment of prostate cancer.

Interventions

PROCEDUREthe robot-assisted laparoscopic radical prostatectomy

We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.

Sponsors

Nanjing University School of Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

* pathologically diagnosed with prostate cancer by prostate biopsy * underwent robot-assisted laparoscopic surgery * the surgery performed by Weidong Gan * the extended pelvic lymphadenectomy (PLA) is performed on patients with high-risk prostate cancer (PSA≥20 ng/ml or Grade Group 4-5 or clinical stage ≥T2c) and those considered to have a possibility of lymph node metastasis based on imaging evaluation.

Exclusion criteria

* Patients with a clinical and pathological TNM stage ≥T3b and N1 * patients with distant metastasis * urinary incontinence before surgery * received neoadjuvant therapy before surgery

Design outcomes

Primary

MeasureTime frameDescription
urinary continence0-6 month after surgerywas defined as using 0-1 pad a day
positive surgical margin2 weeks after surgeryobserved whether the tissue cutting in surgery has tumor cell in surgical margin by pathologist

Secondary

MeasureTime frameDescription
operating timethe day of the surgeryThe start time of the operation refers to the time of incision of the skin at the surgical site. The end time of surgery refers to the time when the skin is sutured.
intraoperative blood lossthe day of the surgeryIntraoperative bleeding was defined as the sum of blood content in blood gauze, blood content in negative pressure suction bottle and blood clot volume.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026